Stay updated on Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now presents the completed study record for nivolumab combined with ipilimumab in metastatic renal cell carcinoma, including study design, participant criteria, measured outcomes, and Swiss locations.SummaryDifference54%

- Check19 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check26 days agoChange DetectedA sitewide NIH notice announces a transition from using “Artificial Intelligence” to “Super Intelligence” terminology. It appears above the unavailable study record.SummaryDifference1%

- Check33 days agoChange DetectedThe footer’s site revision indicator changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study record content, resulting in an inaccessible error screen for the trial details.SummaryDifference18%

Stay in the know with updates to Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial page.